A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Latest Information Update: 29 May 2024
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Agitation
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 18 Apr 2024 Results of Safety, Tolerability, and Efficacy of Brexpiprazole , presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 24 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2022 This trial has been completed in Bulgaria according to European Clinical Trials Database record.